PositiveID is set to begin the first clinical trial of its Easy Check non-invasive breath glucose detection device for type 2 diabetes people.

The company said Easy Check is a non-invasive breath glucose detection device which measures the level of acetone in a patient’s exhaled breath and then correlates that acetone level to a measure of blood glucose, which is under development in Israel.

Easy Check utilizes the company’s FDA-cleared iglucose technology which is based on a patent-pending reagent cell that mixes a patient’s exhaled air with a proprietary chemical compound, thus triggering a chemical reaction.

The reaction is measured and then the Easy Check device’ software interprets the measurement and correlates the patient’s acetone level to the level of glucose in the body.

PositiveID chairman and CEO William Caragol said Easy Check could provide a means for people with diabetes to eliminate the pain associated with taking blood glucose readings, therefore facilitating more frequent testing and improved management of type 2 diabetes.

The Company is also developing GlucoChip, a continuous glucose-sensing microchip, and the iglucose glucometer, a blood glucose meter utilizing iglucose technology.